Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.69), $0.28 better than the analyst estimate of ($2.97). Revenue for the quarter came in at $35.1 million versus the consensus estimate of $28.23 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.